secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vanda Pharmaceuticals Inc. (VNDA)
CIK:        0001347178
Form:       8-K
Filed at:   2026-02-19T23:59:59+00:00
Accession:  0001628280-26-009805
Event type: other
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vanda Pharmaceuticals sets 2025 bonuses, 2026 salaries, and grants RSUs/PSUs to executives
--------------------------------------------------------------------------------

- CEO Polymeropoulos gets $834,326 2025 bonus; 2026 base $994,625, target bonus 80%.
- Other NEOs 2025 bonuses $272k-$282k; 2026 base $576,735-$596,990, target 45%.
- RSUs: 525,000 to CEO, 125,000 to each of four other NEOs; vest in 4 equal annual installments.
- PSUs: target 175,000 (CEO), 40,000 (others); payout 0%-150% based on relative TSR vs Nasdaq Biotech Index over 3 years.
- Compensation Committee used Willis Towers Watson peer analysis in determining compensation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347178/000162828026009805/0001628280-26-009805-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347178/000162828026009805/vnda-20260218.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-009805

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer